237 related articles for article (PubMed ID: 427777)
21. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.
Schroit AJ; Fidler IJ
Cancer Res; 1982 Jan; 42(1):161-7. PubMed ID: 7053846
[TBL] [Abstract][Full Text] [Related]
22. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
Taramelli D; Varesio L
J Immunol; 1981 Jul; 127(1):58-63. PubMed ID: 6787132
[TBL] [Abstract][Full Text] [Related]
23. Macrophage activation for microbicidal activity against Leishmania major: inhibition of lymphokine activation by phosphatidylcholine-phosphatidylserine liposomes.
Gilbreath MJ; Nacy CA; Hoover DL; Alving CR; Swartz GM; Meltzer MS
J Immunol; 1985 May; 134(5):3420-5. PubMed ID: 3980997
[TBL] [Abstract][Full Text] [Related]
24. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
[TBL] [Abstract][Full Text] [Related]
25. [Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice and rats].
Ogura T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):689-96. PubMed ID: 3083782
[TBL] [Abstract][Full Text] [Related]
26. In vitro induction of tumoricidal and suppressor macrophages by lymphokines: possible feedback regulation.
Taramelli D; Holden HT; Varesio L
J Immunol; 1981 Jun; 126(6):2123-8. PubMed ID: 6453155
[TBL] [Abstract][Full Text] [Related]
27. Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity.
Kern DE; Grabstein KH; Okuno K; Schreiber RD; Greenberg PD
J Immunol; 1989 Dec; 143(12):4308-16. PubMed ID: 2687379
[TBL] [Abstract][Full Text] [Related]
28. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.
Kleinerman ES; Schroit AJ; Fogler WE; Fidler IJ
J Clin Invest; 1983 Jul; 72(1):304-15. PubMed ID: 6348087
[TBL] [Abstract][Full Text] [Related]
29. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.
Fogler WE; Fidler IJ
Cancer Res; 1985 Jan; 45(1):14-8. PubMed ID: 3855280
[TBL] [Abstract][Full Text] [Related]
30. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.
Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ
Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
Daemen T; Veninga A; Dijkstra J; Scherphof G
J Immunol; 1989 Apr; 142(7):2469-74. PubMed ID: 2926140
[TBL] [Abstract][Full Text] [Related]
32. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
Phillips NC; Moras ML; Chedid L; Lefrancier P; Bernard JM
Cancer Res; 1985 Jan; 45(1):128-34. PubMed ID: 3838084
[TBL] [Abstract][Full Text] [Related]
33. Production of C3 as a marker of lymphokine-mediated macrophage activation.
Koestler TP; Kirsh R; Kline T; Rieman D; Greig R; Poste G
Cell Immunol; 1984 Aug; 87(1):1-14. PubMed ID: 6378389
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic characterization of human T lymphocyte populations producing macrophage-activating factor (MAF) lymphokines.
Biondi A; Roach JA; Schlossman SF; Todd RF
J Immunol; 1984 Jul; 133(1):281-5. PubMed ID: 6373929
[TBL] [Abstract][Full Text] [Related]
35. Activation of tumoricidal properties in macrophages by lymphokines encapsulated in liposomes.
Fidler IJ; Fogler WE
Lymphokine Res; 1982; 1(3):73-7. PubMed ID: 6765335
[No Abstract] [Full Text] [Related]
36. Defective tumoricidal capacity of macrophages from C3H/HeJ mice.
Ruco LP; Meltzer MS
J Immunol; 1978 Jan; 120(1):329-34. PubMed ID: 627723
[TBL] [Abstract][Full Text] [Related]
37. The induction and augmentation of macrophage tumoricidal responses by platelet-activating factor.
Howard AD; Erickson KL
Cell Immunol; 1995 Aug; 164(1):105-12. PubMed ID: 7634340
[TBL] [Abstract][Full Text] [Related]
38. Dissociation between macrophage tumoricidal capacity and suppressive activity: analysis with macrophage-defective mouse strains.
Boraschi D; Pasqualetto E; Ghezzi P; Salmona M; Bartalini M; Barbarulli G; Censini S; Soldateschi D; Tagliabue A
J Immunol; 1983 Oct; 131(4):1707-13. PubMed ID: 6311895
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators.
Hudson MM; Snyder JS; Jaffe N; Kleinerman ES
Cancer Res; 1988 Sep; 48(18):5256-63. PubMed ID: 3261632
[TBL] [Abstract][Full Text] [Related]
40. Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin.
Mace K; Mayhew E; Mihich E; Ehrke MJ
Cancer Res; 1988 Jan; 48(1):130-6. PubMed ID: 3257160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
